Asian participants' experience in phase 3/3b studies of long‐acting cabotegravir and rilpivirine: Efficacy, safety, pharmacokinetic, and virological outcomes through week 96
Open Access
- 26 December 2023
- journal article
- research article
- Published by Wiley in HIV Medicine
- Vol. 25 (3) , 381-390
Abstract
Objectives: Cabotegravir + rilpivirine (CAB + RPV) dosed monthly or every 2 months is the first complete long‐acting (LA) regimen recommended by treatment guidelines for the maintenance of HIV‐1 virological suppression. This post hoc analysis summarizes outcomes for Asian participants through week 96.Methods: Data from Asian participants naive to CAB + RPV randomized to receive dosing every 4 weeks (Q4W) or every 8 weeks (Q8W) in the FLAIR (NCT02938520) and ATLAS‐2M (NCT03299049) phase 3/3b studies were pooled. The proportion of participants with plasma HIV‐1 RNA ≥50 and n = 17; Q4W, n = 24). At week 96, 83% (n = 34/41) of participants maintained HIV‐1 RNA n = 7/41) had no virological data. No Asian participant met the CVF criterion. Drug‐related adverse events occurred in 44% (n = 18/41) of participants; none were Grade ≥3. All injection site reactions were Grade 1 or 2; median duration was 2 days and most resolved within 7 days (90%, n = 390/435). CAB and RPV trough concentrations remained well above their respective protein‐adjusted 90% inhibitory concentrations (CAB, 0.166 μg/mL; RPV, 12 ng/mL) through week 96.Conclusions: CAB + RPV LA demonstrated high efficacy, with no participants having CVF, and an acceptable safety profile in Asian participants through week 96. These data support CAB + RPV LA as a complete regimen for the maintenance of HIV‐1 virological suppression in Asian individuals.Keywords
Funding Information
- Janssen Pharmaceutica
- ViiV Healthcare
This publication has 16 references indexed in Scilit:
- Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysisAIDS, 2021
- Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority studyThe Lancet, 2020
- Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trialThe Lancet HIV, 2020
- Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 SuppressionNew England Journal of Medicine, 2020
- Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 InfectionNew England Journal of Medicine, 2020
- 1329. Experiences and Emotional Challenges of Antiretroviral Treatment (ART)—Findings from the Positive Perspectives StudyOpen Forum Infectious Diseases, 2019
- Examining the associations between HIV-related stigma and health outcomes in people living with HIV/AIDS: a series of meta-analysesBMJ Open, 2016
- The effect of antiretroviral therapy on all-cause mortality, generalized to persons diagnosed with HIV in the USA, 2009–11International Journal of Epidemiology, 2016
- World Medical Association Declaration of HelsinkiJAMA, 2013
- Drug safety assessment in clinical trials: methodological challenges and opportunitiesTrials, 2012